Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Harpoon Therapeutics, Inc. (HARP) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/12/2022 8-K Quarterly results
01/11/2022 8-K Investor presentation
Docs: "Spearheading Immunotherapies Investor Presentation, dated January 2022"
12/09/2020 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 8, 2020 Harpoon Therapeutics, Inc. Delaware 001-38800 47-3458693 131 Oyster Point Blvd, Suite 300 South San Francisco, California 94080 443-7400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communicat...",
"Harpoon Therapeutics Reports Clinical Progress Across All Four TriTAC ® Pipeline Development Programs",
"Clinical Pipeline Update Presentation"
05/29/2020 8-K Investor presentation
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 29, 2020 Harpoon Therapeutics, Inc. Delaware 001-38800 47-3458693 131 Oyster Point Blvd, Suite 300 South San Francisco, California 94080 443-7400 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications...",
"Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC ® HPN424 at the ASCO20 Virtual Scientific Program",
"Phase 1 HPN424 Interim Data Presentation and Pipeline Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy